stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Return on equity
Teva Pharmaceutical Industries Ltd.'s return on equity over the twelve months to 30 September 2026 was 6.65%, down 14.6 percentage points from fiscal 2025 (21.2%). Over the past ten years it has ranged from −71.1% (fiscal 2017) to 21.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 21.2% | 45.48 |
| FY2024 | −24.3% | (17.58) |
| FY2023 | −6.69% | 17.96 |
| FY2022 | −24.7% | (28.39) |
| FY2021 | 3.74% | 34.29 |
| FY2020 | −30.6% | (24.07) |
| FY2019 | −6.48% | 9.04 |
| FY2018 | −15.5% | 55.58 |
| FY2017 | −71.1% | (71.33) |
| FY2016 | 0.23% | (6.06) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. compare | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.4% |
| UTHR United Therapeutics Corporation compare | 19.1% |
| TEVA Teva Pharmaceutical Industries Ltd. | 6.65% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| TAK Takeda Pharmaceutical Co. compare | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement